The mechanism of action of pirfenidone has not been fully established. Data suggest it has both antifibrotic and anti-inflammatory properties.
It is recommended as an option for patients with a forced vital capacity (FVC) between 50% and 80% predicted, provided it is supplied with the discount agreed in the patient access scheme. It should be discontinued if there is evidence of disease progression, defined as a 10% or greater decline in per cent predicted FVC within a 12 month period.
Look out for Esbriet in the June edition of MIMS.